Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
Status:
Not yet recruiting
Trial end date:
2028-10-20
Target enrollment:
Participant gender:
Summary
This study is a Phase IIIb extension trial following the "randomized, double-blind,
placebo-controlled, entecavir basic treatment, multi-center Phase III clinical trial of
hydroxnidone capsules in the treatment of liver fibrosis of chronic viral hepatitis B".
The main objective of this study is to evaluate the effectiveness and the safety of
hydroxyeidone capsules for long-term treatment of patients with chronic viral hepatitis B
liver fibrosis.